{
    "id": 2434,
    "fullName": "EGFR D761Y",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR D761Y lies within the protein kinase domain of the Egfr protein (UniProt.org). D761Y has not been individually characterized however, transforms cells in culture and is associated with resistance to tyrosine kinase inhibitors with a co-occurring EGFR L858R (PMID: 28424065), and therefore, its effect on Egfr protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 16679,
                    "pubMedId": 28424065,
                    "title": "Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28424065"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "D761Y",
    "createDate": "10/23/2014",
    "updateDate": "11/04/2019",
    "referenceTranscriptCoordinates": {
        "id": 135561,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55174818G>T",
        "cDna": "c.2281G>T",
        "protein": "p.D761Y",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2225,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L858R and EGFR D761Y demonstrated decreased sensitivity to Iressa (gefitinib) in culture (PMID: 17085664).",
            "molecularProfile": {
                "id": 6332,
                "profileName": "EGFR D761Y EGFR L858R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2798,
                    "pubMedId": 17085664,
                    "title": "Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17085664"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2996,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing EGFR L858R and D761Y demonstrated decreased sensitivity to Nerlynx (neratinib) in culture (PMID: 17085664).",
            "molecularProfile": {
                "id": 6332,
                "profileName": "EGFR D761Y EGFR L858R"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 2798,
                    "pubMedId": 17085664,
                    "title": "Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17085664"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3000,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EKI-285 (CL-387,785) inhibited growth of transformed cells expressing EGFR L858R and EGFR D716Y in culture (PMID: 17085664).",
            "molecularProfile": {
                "id": 6332,
                "profileName": "EGFR D761Y EGFR L858R"
            },
            "therapy": {
                "id": 2911,
                "therapyName": "EKI-285",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2798,
                    "pubMedId": 17085664,
                    "title": "Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17085664"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3248,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with EGFR L858R-mutant non-small lung cancer that developed resistance to Iressa (gefitinib) was demonstrated to have acquired a secondary EGFR D761Y mutation (PMID: 17085664).",
            "molecularProfile": {
                "id": 6332,
                "profileName": "EGFR D761Y EGFR L858R"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 2798,
                    "pubMedId": 17085664,
                    "title": "Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17085664"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20102,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Tarceva (erlotinib) treatment resulted in stable disease with an overall survival of 9 months in a patient with non-small cell lung cancer harboring EGFR G719A and EGFR D761Y (PMID: 31715539).",
            "molecularProfile": {
                "id": 34875,
                "profileName": "EGFR G719A EGFR D761Y"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17697,
                    "pubMedId": 31715539,
                    "title": "Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31715539"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2316,
            "profileName": "EGFR D761Y",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 6332,
            "profileName": "EGFR D761Y EGFR L858R",
            "profileTreatmentApproaches": [
                {
                    "id": 4856,
                    "name": "EGFR Inhibitor 3rd gen",
                    "profileName": "EGFR D761Y EGFR L858R"
                }
            ]
        },
        {
            "id": 34875,
            "profileName": "EGFR G719A EGFR D761Y",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135561,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55174818G>T",
            "cDna": "c.2281G>T",
            "protein": "p.D761Y",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}